Hutchin Hill Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hutchin Hill Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-41,100	Closed	-$521K	–	817
2017 Q3	$521K	Sell	41,100 -10,900	-21%	-$139K	0.02%	524
2017 Q2	$617K	Buy	+52,000	New	+$647K	0.02%	636
2017 Q1	–	Sell	-259,100	Closed	-$4.19M	–	1127
2016 Q4	$4.19M	Buy	259,100 +167,000	+181%	+$3.03M	0.14%	177
2016 Q3	$1.67M	Sell	92,100 -118,800	-56%	-$2.32M	0.03%	273
2016 Q2	$3.47M	Sell	210,900 -46,000	-18%	-$744K	0.12%	124
2016 Q1	$4.26M	Buy	+256,900	New	+$4.49M	0.12%	207
2015 Q4	–	Sell	-39,400	Closed	-$781K	–	812
2015 Q3	$781K	Buy	+39,400	New	+$1.24M	0.03%	438
2014 Q1	–	Sell	-11,000	Closed	-$84K	–	778
2013 Q4	$84K	Buy	+11,000	New	+$59.3K	0.01%	498

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hutchin Hill Capital's HZNP Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 41,100 shares — an estimated $521K sold.

Hutchin Hill Capital first reported a position in HZNP in Q4 2013 and held it in 8 quarters. The position peaked at $4.26M in Q1 2016. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

Hutchin Hill Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Hutchin Hill Capital sold 41,100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $521K.
Hutchin Hill Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 8 quarters.
Hutchin Hill Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.26M in Q1 2016.
183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.